Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. [electronic resource]
Producer: 20150330Description: 1010-4 p. digitalISSN:- 1525-1438
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Carboplatin -- administration & dosage
- Carcinoma, Ovarian Epithelial
- Cyclophosphamide -- administration & dosage
- Cystadenocarcinoma, Serous -- drug therapy
- Deoxycytidine -- administration & dosage
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Neoplasm Grading
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Peritoneal Neoplasms -- drug therapy
- Prognosis
- Retrospective Studies
- Survival Rate
- Topotecan -- administration & dosage
- Young Adult
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.